Dexmedetomidine /ml
PreclinicalSmall molecule
Dexmedetomidine /ml is one of 11 small molecule programs targeting Polyuria. It is currently in Preclinical.
2
Indications
6
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Polyuria
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Vesicare
AstellasApproved
Enablex
AbbVieApproved
Toviaz
PfizerApproved
Oxytrol
WWim Janssens
Approved
Pitressin
AAultman Health Foundation
Approved
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Dexmedetomidine /ml
SSt. Justine's Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dexmedetomidine1 trial
Septic Shock1 trial
Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock
Terminated·—·Phase 3·NCT03953677·32 enrolled
Alcohol Withdrawal1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexmedetomidine /ml. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSt. Justine's Hospital